octreotide acetate

P4, N=62, Recruiting, Boston Children's Hospital | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Not yet recruiting --> Recruiting

P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

PRRT combined with everolimus-based immunosuppression has demonstrated controllable safety and preliminary antitumor activity in patients with relapsed NETLM after LT who have been strictly screened, but myelosuppression requires close monitoring and timely symptomatic treatment.

Initial long-acting octreotide treatment was ineffective in controlling hyperthyroidism and was discontinued after 5 months. Despite SSTR2/5 positivity, suboptimal response to octreotide suggests tumor heterogeneity or downstream signaling defects. Preoperative Lugol's solution should be considered when SSAs and methimazole fail.

The patient underwent aortic valve replacement followed by long-acting octreotide therapy...This case represents an exceptionally rare scenario of pancreatic neuroendocrine tumor in a patient with prior lung carcinoid tumor and raises the critical question of pancreatic metastasis versus a second primary NET in the absence of hereditary syndromes. It underscores the need for heightened vigilance for second primary malignancies (SPMs) and atypical metastatic patterns in patients with a history of NETs and highlights the importance of multidisciplinary evaluation for accurate classification and optimal management.

P=N/A, N=62, Not yet recruiting, Boston Children's Hospital

From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach.

P3, N=332, Active, not recruiting, Camurus AB | Trial completion date: Dec 2027 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026

Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety and patient-specific parameters to optimize outcomes.

P1, N=19, Completed, Roswell Park Cancer Institute | Recruiting --> Completed | N=14 --> 19 | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Dec 2025 --> Feb 2025

Higher blood tumor mutational burden (bTMB) was linked to poor prognosis in Octreotide LAR-treated patients and correlated with higher Ki-67 levels, and alterations in the TM, mTOR, and Notch pathways...TERT mutations, bTMB, and MSAF predict PFS or OS. Co-occurring TM, mTOR, and NOTCH pathway alterations highlight ctDNA's potential in guiding precision medicine.

P=N/A, N=70, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2025 --> Dec 2025